ACTRN12606000345583
Completed
Phase 1
Phase Ia Safety and Pharmacokinetic Study of Oral NV-196 in Patients with Solid Tumours
Not provided0 sites12 target enrollmentAugust 11, 2006
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Not provided
- Enrollment
- 12
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients meeting all of the following criteria will be considered for admission to the study:a)Patients must have a solid malignancy that has become stable on current treatment. For the purposes of this study, stable disease is defined as no change of anti\-cancer therapy within the last 28 days (hormone therapy or on observation), not including supportive therapies. Patients just completing chemotherapy or radiotherapy are eligible, provided these treatments were last administered more than 28 days prior to NV\-196 administration.b) Patients must be able to understand the risks and benefits of the study and give written informed consent to participation. c)Patients must have an estimated life\-expectancy of at least 3 months. d)Patients must have: •acceptable renal and hepatic function evidenced by a serum creatinine \< 1\.5 mg/dl and serum transaminase levels less than or equal to 3 x the upper limit of normal for the reference laboratory •bilirubin \< 20 micro mol/L,•adequate haematological function. e)Patients must have a Karnofsky Performance Score of at least 60%. f)Patients of childbearing potential must agree to use an acceptable method of contraception. g)Patients have no evidence of central nervous system malignancy.
Exclusion Criteria
- •Patients presenting with any of the following will not be included in the study:a)Patients who are on a concurrent investigational drug study or who have had any treatment with any investigational agents within 4 weeks of commencing the study.b)Patients with active infection.c)Patients who have not recovered from the acute effects of any prior anti\-neoplastic therapy or radiotherapy.d)Patients who, in the opinion of the investigator, are more suitable for active treatment with an anti\-cancer agent.e)Patients with concurrent severe and/or uncontrolled medical disease (eg. uncontrolled diabetes, hypertension, ischemic heart disease, congestive heart failure, etc.).f)Patients with a history of chronic active hepatitis or liver cirrhosis.g)Patients with HIV.h)Patients who are pregnant or lactating.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Phase 1/2 Pharmacokinetic and Safety Study of Oral Phenoxodiol in Patients with Hormone-Refractory Prostatic AdenocarcinomaACTRN12605000512628Marshall Edwards Pty Ltd24
Active, not recruiting
Not Applicable
A Phase IIa Safety study of oral administration of anti-CD3 monoclonal antibody in non-responder genotype-I chronic Hepatitis C subjects, a single-blind, randomized, controlled single-center studyEUCTR2011-001071-40-PLInSpira Medical AB36
Active, not recruiting
Not Applicable
A Phase IIa Safety study of oral administration of anti-CD3 monoclonal antibody in non-responder genotype-I chronic Hepatitis C subjects, a single-blind, randomized, controlled multi-center studyin non-responder genotype-I chronic Hepatitis C subjectsMedDRA version: 14.0Level: LLTClassification code 10047457Term: Viral hepatitis CSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.0Level: LLTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2011-001071-40-ATInSpira Medical AB36
Not yet recruiting
Phase 1
The First Pharmacokinetic Study and Safety of of Oral Nano-emulsified Cannabidol (CBD-NE) in Healthy VolunteersCannabidiol (CBD) is a non-psychoactive extract from the hemp plant. CBD is involved in the body'TCTR20231114007Chakrabongse Aiewtrakoon72
Active, not recruiting
Not Applicable
A Phase 1B Study of the Safety and Pharmacokinetics of Ritonavir-Boosted Elvitegravir (GS-9137/r) Plus a Background Regimen (BR) in HIV-1 Infected, Antiretroviral Treatment-Experienced AdolescentsEUCTR2008-003917-29-GBGilead Sciences Incorporated24